Abstract
Under double-blind protocol, a controlled comparison was made between a new cephalosporin, cephacetrile, and cephalothin or cephaloridine. The patient's primary physician determined the indications for treatment, and the dosage was uniform for each route of administration. Infecting strains of staphylococci and Proteus mirabilis had a lower median inhibitory concentration for cephalothin than cephacetrile; the opposite was true for Escherichia coli and Klebsiella species. The average peak serum level 1 h after a dose of 2 g intravenously was 74.9 ± 21 and 21.5 ± 8.7 μg/ml for cephacetrile and cephalothin, respectively; 6 h after the dose, the respective levels were 12.4 ± 4.3 and 3.7 ± 0.9 μg/ml. Renal clearances were similar and the plasma clearance was proportional to the serum levels. In the urine, the concentration of cephacetrile was three times higher than that of cephalothin. Based on a percentage of therapeutic potential, success in the treatment of infections with susceptible organisms was 42 and 44% for the two different drug regimens. Initial bacterial resistance was found in about one-fifth of infections, and concomitant therapy with other drugs was practiced in one-half of the treatment courses. Intravenous use of cephacetrile was discontinued prematurely more often than was use of cephalothin, suggesting less tolerance. Although there was no overt toxicity, more than 75% of patients on either regimen had some form of unwanted response to treatment, the most common being superinfection. From this limited but controlled experience, cephacetrile can be considered comparable to cephalothin in antimicrobial treatment and overall side reactions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Brogard J. M., Haegele P., Dorner M., Lavillaureix J. Biliary excretion of a new semisynthetic cephalosporin, cephacetrile. Antimicrob Agents Chemother. 1973 Jan;3(1):19–23. doi: 10.1128/aac.3.1.19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Davies J. E., Rownd R. Transmissible multiple drug resistance in Enterobacteriaceae. Science. 1972 May 19;176(4036):758–768. doi: 10.1126/science.176.4036.758. [DOI] [PubMed] [Google Scholar]
- Hodges G. R., Scholand J. F., Perkins R. L. Cephacetrile: clinical evaluation in 27 patients. Antimicrob Agents Chemother. 1973 Feb;3(2):228–234. doi: 10.1128/aac.3.2.228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kirby W. M., De Maine J. B., Serrill W. S. Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients. Postgrad Med J. 1971 Feb;47(Suppl):41–46. [PubMed] [Google Scholar]
- LEE C. C., HERR E. B., Jr, ANDERSON R. C. Pharmacological and toxicological studies on cephalotin. Clin Med (Northfield) 1963 Jun;70:1123–1138. [PubMed] [Google Scholar]
- MARCHASIN S., WALLERSTEIN R. O., AGGELER P. M. VARIATIONS OF THE PLATELET COUNT IN DISEASE. Calif Med. 1964 Aug;101:95–100. [PMC free article] [PubMed] [Google Scholar]
- Nissenson A. R., Levin N. W., Parker R. H. Effect of renal failure and hemodialysis on cephacetrile pharmacokinetics. Clin Pharmacol Ther. 1972 Nov-Dec;13(6):887–894. doi: 10.1002/cpt1972136887. [DOI] [PubMed] [Google Scholar]
- Sabath L. D., Casey J. I., Ruch P. A., Stumpf L. L., Finland M. Rapid microassay for circulating nephrotoxic antibiotics. Antimicrob Agents Chemother (Bethesda) 1970;10:83–90. [PubMed] [Google Scholar]
- Smith J. T., Hamilton-Miller J. M., Knox R. Bacterial resistance to penicillins and cephalosporins. J Pharm Pharmacol. 1969 Jun;21(6):337–358. doi: 10.1111/j.2042-7158.1969.tb08267.x. [DOI] [PubMed] [Google Scholar]